RNS Number:8203I
Schering AG
17 March 2003

"ABOVE" MS Study with Betaferon(R) to explore benefits of increasing dose and
frequency of beta interferon

Berlin, March 17, 2003 - Schering AG, Germany (FSE: SCH, NYSE: SHR) announced
today that its U.S. subsidiary, Berlex Laboratories, Inc., is starting a
clinical trial to evaluate the effect of an increased beta interferon dose and
frequency in patients with relapsing-remitting multiple sclerosis (MS) or
patients being treated with a lower-dose, once-weekly MS therapy.

The study, known as "ABOVE" (Interferon beta-1a vs. Interferon beta-1b
Observation of Efficacy), will compare the outcome of continuing once-weekly
Avonex(R) (interferon beta-1a) versus changing to a high-dose, high-frequency
regimen with Betaferon(R) (interferon beta-1b) for SC Injection.

About ABOVE

In this randomized, rater-blinded study, patients diagnosed with
relapsing-remitting MS who currently are being treated with Avonex(R) - and have
received the drug for at least the previous six months - will randomly be
assigned to either continue Avonex(R) treatment or change to Betaferon(R).
Patients who are treated with Betaferon(R) will increase their dose over several
weeks according to the study protocol. Patients in both treatment arms will
participate in the study for a total of two years. Efficacy will be measured by
the number of patients who are relapse-free at the end of the treatment period,
comparing those treated with Betaferon(R) and those treated with Avonex(R).

This will be the largest therapeutic MS study ever conducted, involving more
than 75 research centers nationwide. Patient enrollment is beginning immediately
and will continue through 2004.

Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Gynecology&Andrology, Diagnostics&
Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for
disabling diseases in the fields of the central nervous system, oncology and
cardiovascular system. As a global player with innovative products Schering AG
aims for leading positions in specialized markets worldwide. With in-house R&D
and supported by an excellent global network of external partners, Schering AG
is securing a promising product pipeline. Using new ideas, Schering AG aims to
make a recognized contribution to medical progress and strives to improve the
quality of life: making medicine work

This press release has been published by Corporate Communication of Schering AG,
Berlin, Germany.

Your contacts at Corporate Communication:

Business: Dr Friedrich von Heyl, T: +49-30-468 152 96;
friedrich.vonheyl@schering.de

Investor Relations: Peter Vogt, T: +49-30-468 128 38; peter.vogt@schering.de

Pharma: Dr Claudia Schmitt, T: +49-30-468 158 05, claudia.schmitt@schering.de

Your contacts in the US:

Media Relations: Jeanine O'Kane, T:+1-973-487 2095, jeanine_O'kane@berlex.com

Investor Relations: Joanne Marion, T: +1-973-487 2164, joanne_marion@berlex.com

Find additional information at: www.schering.de/eng



Certain statements in this press release that are neither reported financial
results nor other historical information are forward-looking statements,
including but not limited to, statements that are predictions of or indicate
future events, trends, plans or objectives. Undue reliance should not be placed
on such statements because, by their nature, they are subject to known and
unknown risks and uncertainties and can be affected by other factors that could
cause actual results and Schering AG's plans and objectives to differ materially
from those expressed or implied in the forward-looking statements. Certain
factors that may cause such differences are discussed in our Form 20-F and Form
6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG
undertakes no obligation to update publicly or revise any of these
forward-looking statements, whether to reflect new information or future events
or circumstances or otherwise.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RESBXGDXSSBGGXR